Neurodegeneration – Products

Oxford Nanopore Technologies, announced a new collaboration with UK Biobank to create the world’s first comprehensive, large-scale epigenetic dataset.

This whitepaper explores the translational and clinical applications of IMC to develop biomarkers and future treatment strategies in neuro-oncology and neurodegenerative studies.

This application note demonstrates how imaging mass cytometry (IMC) is transforming neurodegeneration research, providing detailed visualization of protein aggregates, neuron populations and inflammatory cell interactions.

Aneuro provides high-quality Tau products — proteins, fibrils, cell lines, and antibodies. These products assist researchers in investigating Tau's role in neurodegenerative diseases and developing potential therapies.

iPSC-derived organoid technology drives advances in drug discovery, disease modeling, and personalized medicine. Our cardiac, brain, intestinal, and liver organoids are essential for disease research and therapeutic development.

APOE genotyping allows assessment of a patient’s risk for adverse effects from new anti-amyloid therapy for Alzheimer’s.

This whitepaper explores innovative proteomic tools that offer insights into protein signatures and that can serve as biomarkers for aging.

New protein sequencing ‘proof-of-concept' method published in Nature shows promise in sequencing long, intact protein strands at single molecule resolution.

Key scientific achievement advances the joint neuroscience pipeline and earns a payment of US$ 25 m to Evotec to progress further research.

On July 29, 2024, the U.S. FDA approved Alpha Cognition Inc.'s ALPHA-1062 (Zunveyl®), an Acetylcholinesterase (AChE) inhibitor, for treating mild-to-moderate Alzheimer’s disease.